Review proposes unified theory for opposing GIP receptor drug strategies
A new review offers one explanation for why drugs that switch the GIP receptor on and drugs that switch it off have both been pursued, but it adds no new patient data or treatment guidance.
A review published May 29 in the Journal of Clinical Medicine proposes a single biological framework for a question that has divided metabolic drug research: why programs have pursued both drugs that activate the GIP receptor and drugs that block it [1].
The article is titled "The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs" [1]. Its proposed explanation is that GIP receptor agonism acts on GABAergic neurons, while antagonism releases a brake on GLP-1 action in glutamatergic neurons [1]. In other words, the two opposing strategies may work through different cell populations rather than contradicting each other.
The authors are Jonathan D. Douros, Stephanie A. Mowery and Patrick J. Knerr, all at the Indiana Biosciences Research Institute in Indianapolis [1]. Their backgrounds are in incretin drug discovery. Knerr, a peptide medicinal chemist and the institute's vice president of metabolic translational research, previously led discovery efforts at the Novo Nordisk Research Center Indianapolis that produced multiple long-acting incretin analogs reaching clinical testing for type 2 diabetes, obesity and related indications, and he joined the institute in 2024 [1]. Douros, a pharmacologist, joined the same Novo Nordisk center in 2020 and became associate director of biology and pharmacology in 2022, and he is now a senior scientific director at the institute [1]. Mowery is a receptor pharmacologist with more than 10 years of industrial experience who worked as a senior scientist in Novo Nordisk's biology and pharmacology group in Indianapolis before joining the institute [1].
The journal record shows the manuscript was submitted May 2, 2025, revised May 23, accepted May 24 and published May 29 [1]. It appears as article 3812 in volume 14, issue 11 of the Journal of Clinical Medicine and carries the DOI 10.3390/jcm14113812 [1]. The article is open access, and it is labeled a review, meaning it assembles existing evidence rather than reporting new trial results [1].
Why it matters for patients
The review is an argument about receptor biology, not a study of people [1]. It reports no patient outcomes, no head-to-head comparison of medicines and no new safety findings [1]. Nothing in it changes the prescribing information for any drug, and it does not identify which patients might respond better to a GIP-based approach than to a GLP-1-based one; that has not been reported [1].
That distinction matters because the paradox the authors describe is a scientific one. Both directions of drug development exist because evidence supported each of them, and the review's purpose is to examine that evidence rather than to settle which strategy is better in the clinic [1]. For anyone taking or considering a GLP-1 or GIP-related medicine, this publication does not provide a reason to change treatment, and it does not contain data on weight loss, blood sugar or side effects [1].
What happens next
No follow-up experiments, clinical studies or timelines tied to the proposed framework have been disclosed [1]. The full text is freely available through the journal's open access policy, so the authors' complete review of the supporting evidence can be read directly [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.